Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol
NCT00768274 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 72
Last updated 2022-11-04
Summary
The purpose of this study is to investigate an oral formulation of RVX000222 for safety, pharmacokinetic and efficacy in healthy subjects.
Conditions
- Dyslipidemia
- Atherosclerosis
- Acute Coronary Syndrome
- Cardiovascular Disease
Interventions
- DRUG
-
RVX000222
RVX000222 twice daily (b.i.d.) for 28 days
- DRUG
-
Placebo twice daily (b.i.d.) for 28 days
Sponsors & Collaborators
-
Resverlogix Corp
lead INDUSTRY
Principal Investigators
-
Allan Gordon, MD, PhD · Resverlogix Corp
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2008-09-30
- Primary Completion
- 2009-08-31
- Completion
- 2009-08-31
Countries
- United States
Study Locations
More Related Trials
-
Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet
NCT01853800 ·Status: COMPLETED ·Phase: PHASE1
-
To Assess Safety, Tolerability and Pharmacokinetics of BI 416970 in Healthy Male Volunteers
NCT02093819 ·Status: COMPLETED ·Phase: PHASE1
-
An Open-label Single Dose Randomized, Parallel Group Study Followed by Single-blind Repeat Dosing, to Compare the Relative Bioavailability of GSK2212836.
NCT00996268 ·Status: COMPLETED ·Phase: PHASE1
-
Tolerability and Pharmacokinetics/-Dynamics of BIBT 986 BS in Healthy Male Subjects
NCT02254083 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple, Rising Oral Doses of BI 11634 Oral Solution in Healthy Male Volunteers
NCT02214940 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics and Relative Bioavailability of 11634 Immediate Release Tablet in Healthy Male Volunteers
NCT02214927 ·Status: COMPLETED ·Phase: PHASE1
-
A Human Phase I Absolute Bioavailability Study of PRT054021 in Healthy Male Volunteers
NCT01765868 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers
NCT07141199 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 113823 Powder in Bottle (PiB) and Tablet in Healthy Male Volunteers
NCT02259972 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers
NCT01954238 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BIIB 722 CL and HPβCD in Young Healthy Male Volunteers
NCT02224079 ·Status: COMPLETED ·Phase: PHASE1
-
Relative Bioavailability Study in Healthy Subjects Comparing 2 Dry Powder Oral Suspensions of Rivaroxaban Under Fasting and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions
NCT02367027 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 11634 Solution in Healthy Male Volunteers
NCT02214914 ·Status: COMPLETED ·Phase: PHASE1
-
Bioavailability Study of K0706 in Healthy Subjects
NCT03316820 ·Status: COMPLETED ·Phase: PHASE1
-
Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Impaired Liver Function and Healthy Participants Matched for Age-, Gender-, and Weight
NCT04366622 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Relative Bioavailability of Three Immediate-Release Tablet Formulations of ABBV-903 in Healthy Adult Volunteers
NCT06078202 ·Status: WITHDRAWN ·Phase: PHASE1
-
3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule
NCT02034773 ·Status: COMPLETED ·Phase: PHASE1
-
Safety Tolerability and Pharmacokinetic of BI 411034
NCT01581684 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Pharmacokinetics, and Pharmacodynamics of BIRT 2584 XX Administered as Multiple Doses and Safety and Pharmacokinetics of BIRT 2584 XX Administered With and Without Food as Single Dose to Healthy Male Volunteers
NCT02256761 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Relative Bioavailability of Roxadustat Following a Single Dose of Pediatric Azo Dye-free Tablet Formulation and Pediatric Azo Dye-free Mini-tablet Formulation Compared to a Single Dose of Azo Dye-containing Tablet Formulation in Healthy Adult Subjects
NCT03960489 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose
NCT01367496 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants
NCT06849791 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 10773 in Healthy Male Subjects
NCT02172170 ·Status: COMPLETED ·Phase: PHASE1
-
A Bioavailability and Pharmacokinetic Study of Subcutaneous and Intravenous RO6811135 in Healthy Volunteers
NCT01802853 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of BI 201335 NA and Bioavailability in Healthy Male Subjects
NCT02182323 ·Status: COMPLETED ·Phase: PHASE1